这家知名药企，3.56亿购买重要资产

Core Viewpoint - Zhaoli Pharmaceutical is acquiring a multi-element injection asset group for 356 million yuan, aiming to enhance its product portfolio and market presence in the pediatric and obstetric fields [1][4][11]. Group 1: Acquisition Details - Zhaoli Pharmaceutical announced the acquisition of the multi-element injection asset group from Tibet Future Biopharmaceutical Co., Ltd. for a total price of 356 million yuan, including tax [1][11]. - The asset group includes three types of multi-element injections, specifically designed for infants, pregnant women, and patients requiring intravenous nutrition [2][13]. Group 2: Strategic Intent - The acquisition is part of Zhaoli Pharmaceutical's strategy to create a comprehensive health product and service chain covering all age groups, from children to the elderly [2][14]. - The company aims to leverage its existing marketing strengths and the sales channels of Tibet Future to facilitate the rapid entry and penetration of new products [15]. Group 3: Financial Performance - The asset group is projected to achieve a net profit of 45.79 million yuan from January to September 2025, indicating strong profitability [3][14]. - Zhaoli Pharmaceutical reported a revenue of 2.28 billion yuan in the first three quarters of 2025, reflecting an 11.48% year-on-year growth, with a net profit of 509 million yuan, up 22.51% [4][17]. Group 4: Market Context - The multi-element injection market has seen a decline in sales since 2021, with a total market sales of only 1.44 billion yuan in 2024, down 16.32% year-on-year [8][20]. - The competitive landscape is concentrated, with Aquitaine Pharmaceuticals holding a dominant market share of 50.45%, while Tibet Future's sales have decreased by 22.17% to 447 million yuan in 2024 [20][22].